0
0
LONDON — A groundbreaking clinical trial has demonstrated that a monthly antibody injection can help nearly all patients with severe, steroid-dependent asthma significantly reduce or entirely stop taking daily oral corticosteroids, a treatment regimen notorious for its severe long-term health risks.
The findings from the WAYFINDER study, led by researchers at King’s College London and published last week in The Lancet Respiratory Medicine, suggest a major shift in how the most difficult-to-treat forms of asthma could be managed.
Breaking the Steroid Cycle
For the estimated 3% to 10% of asthma patients with severe, uncontrolled disease, daily oral corticosteroids (OCS) like prednisone are often a last resort to keep airways open. While effective, these drugs act as a “blunt instrument,” suppressing the immune system globally and causing debilitating side effects ranging from diabetes and osteoporosis to adrenal failure and weight gain.
The new study tested tezepelumab (marketed as Tezspire), a biologic drug that targets the inflammation “cascade” at its source. The trial followed 298 adults with severe asthma who required daily steroid tablets to control their symptoms.
The results were striking:
-
90% of patients were able to reduce their daily steroid dose to 5mg or less by the end of the year-long study.
-
Over 50% completely stopped taking oral steroids without losing control of their asthma.
-
Two-thirds of participants experienced no asthma attacks (exacerbations) during the 52-week period.
“The WAYFINDER study is an important step forward for patients with the most severe form of asthma who require daily oral steroids in order to achieve reasonable disease control,” said Professor David Jackson, lead author and Professor of Respiratory Medicine at King’s College London.
Targeting the “Alarm” Bell
Tezepelumab works differently from previous biologic treatments. While older drugs target specific immune cells like eosinophils, tezepelumab blocks a protein called thymic stromal lymphopoietin (TSLP). TSLP acts as an upstream “alarm bell” released by the lining of the lungs in response to triggers like viruses, allergens, or pollution.
By blocking this initial alarm, the drug prevents the inflammatory response before it starts, rather than trying to clean up the inflammation after it has spread.
“As tezepelumab also suppresses allergy-related symptoms and improves chronic rhinosinusitis as well, the results are particularly exciting for patients with severe asthma who suffer with both upper and lower airway symptoms,” Professor Jackson added.
The Hidden Cost of “The Necessary Evil”
The study’s significance lies largely in its potential to liberate patients from the burden of oral steroids. Long-term use of these drugs is associated with a cumulative toxicity that can be more damaging than the asthma itself.
“Oral steroids are a double-edged sword,” explains Dr. Elena Rodriguez, a pulmonologist not involved in the study. “They save lives during an acute attack, but when used daily for months or years, they systematically damage the body. We see patients developing cataracts, thinning skin, brittle bones, and difficult-to-manage diabetes. Finding a way to get patients off these drugs is the ‘holy grail’ of severe asthma care.”
A Shift in Standard Care?
The WAYFINDER trial was an open-label, single-arm study, meaning all participants received the drug and knew they were taking it. This design differs from a “blinded” placebo-controlled trial, which is the gold standard for testing efficacy.
However, the magnitude of the benefit observed — specifically the high rate of complete steroid cessation — offers compelling evidence of the drug’s real-world impact. Previous placebo-controlled trials like the SOURCE study had shown mixed results regarding steroid reduction, but the WAYFINDER study allowed for a more personalized, slow tapering of steroids which may account for the superior outcomes.
Dr. Samantha Walker, Director of Research & Innovation at Asthma + Lung UK, called the findings a “promising sign.”
“This is an incredibly encouraging development for the future of asthma care that could transform the lives of people with severe asthma,” Walker said. “It’s vital that research into new types of treatment continues.”
Practical Implications
For patients currently relying on daily prednisone or similar steroids, these findings suggest that a conversation with a specialist may be warranted. Tezepelumab is already approved for use in many countries, including the US and UK, for severe asthma.1
While the drug is administered as a monthly injection, its ability to replace a2 daily regimen of pills could simplify treatment while sparing patients from the cumulative toxicity of steroids.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Primary Study: Jackson, D. J., et al. (2025). “Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial.” The Lancet Respiratory Medicine. DOI: 10.1016/S2213-2600(25)00359-5.
